BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 6139795)

  • 1. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfasalazine and 5-ASA compounds.
    Allgayer H
    Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy of inflammatory bowel disease.
    Sack DM; Peppercorn MA
    Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphasalazine in inflammatory bowel disease: recent advances.
    Cooper BT
    N Z Med J; 1986 Oct; 99(811):757-9. PubMed ID: 2877428
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
    Martin F
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
    Van Gossum A
    Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.
    Peppercorn MA
    Ann Intern Med; 1984 Sep; 101(3):377-86. PubMed ID: 6147110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salazopyrin and its newer analogues in the treatment of inflammatory bowel disease.
    Banatwala N
    J Pak Med Assoc; 1985 Mar; 35(3):64-8. PubMed ID: 2860256
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease.
    van Hees PA
    Acta Gastroenterol Belg; 1987; 50(5):555-9. PubMed ID: 2902723
    [No Abstract]   [Full Text] [Related]  

  • 14. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 18. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
    Sutherland LR; May GR; Shaffer EA
    Ann Intern Med; 1993 Apr; 118(7):540-9. PubMed ID: 8095128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.